DK2026769T3 - Tolagstablet til forebyggelse af kardiovaskulære begivenheder - Google Patents

Tolagstablet til forebyggelse af kardiovaskulære begivenheder

Info

Publication number
DK2026769T3
DK2026769T3 DK07725528.9T DK07725528T DK2026769T3 DK 2026769 T3 DK2026769 T3 DK 2026769T3 DK 07725528 T DK07725528 T DK 07725528T DK 2026769 T3 DK2026769 T3 DK 2026769T3
Authority
DK
Denmark
Prior art keywords
prevention
layer tablet
cardiovascular events
cardiovascular
events
Prior art date
Application number
DK07725528.9T
Other languages
English (en)
Inventor
Marta Guerrero
Antonio Guglietta
Anna Orriols
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38556680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2026769(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrer Int filed Critical Ferrer Int
Application granted granted Critical
Publication of DK2026769T3 publication Critical patent/DK2026769T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07725528.9T 2006-05-24 2007-05-24 Tolagstablet til forebyggelse af kardiovaskulære begivenheder DK2026769T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200601355A ES2300188B1 (es) 2006-05-24 2006-05-24 Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
PCT/EP2007/004631 WO2007134870A1 (en) 2006-05-24 2007-05-24 Bilayer tablet for preventing cardiovascular events

Publications (1)

Publication Number Publication Date
DK2026769T3 true DK2026769T3 (da) 2010-07-19

Family

ID=38556680

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07725528.9T DK2026769T3 (da) 2006-05-24 2007-05-24 Tolagstablet til forebyggelse af kardiovaskulære begivenheder

Country Status (23)

Country Link
US (1) US20090196922A1 (da)
EP (1) EP2026769B1 (da)
JP (1) JP2009537583A (da)
KR (1) KR20090020577A (da)
CN (1) CN101453992A (da)
AR (1) AR061047A1 (da)
AT (1) ATE460924T1 (da)
AU (1) AU2007253580B2 (da)
BR (1) BRPI0712267A2 (da)
CA (1) CA2652838A1 (da)
CY (1) CY1110097T1 (da)
DE (1) DE602007005372D1 (da)
DK (1) DK2026769T3 (da)
ES (2) ES2300188B1 (da)
MX (1) MX2008014782A (da)
NO (1) NO20084998L (da)
PL (1) PL2026769T3 (da)
PT (1) PT2026769E (da)
RU (1) RU2445088C2 (da)
SI (1) SI2026769T1 (da)
TW (1) TW200812647A (da)
UY (1) UY30365A1 (da)
WO (1) WO2007134870A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
CN101820863A (zh) * 2007-10-10 2010-09-01 马林克罗特贝克公司 直接可压制的高功能性颗粒状微晶纤维素基赋形剂、其制备方法和用途
ES2689107T3 (es) * 2009-11-13 2018-11-08 Astrazeneca Ab Formulaciones de tabletas bicapa
WO2011088152A1 (en) * 2010-01-12 2011-07-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
US9993422B2 (en) 2012-04-18 2018-06-12 SpecGx LLC Immediate release, abuse deterrent pharmaceutical compositions
CA2888278A1 (en) * 2012-10-15 2014-04-24 Isa Odidi Oral drug delivery formulations
PL2968182T3 (pl) 2013-03-15 2018-10-31 SpecGx, LLC Zniechęcająca do nadużywania stała postać dawkowania dla natychmiastowego uwalniania z funkcjonalnym rowkiem
HUE065006T2 (hu) 2014-07-03 2024-04-28 SpecGx LLC Nem-cellulóz poliszacharidokat tartalmazó, visszaélés-gátló, azonnali felszabadulású készítmények
CA2990855A1 (en) * 2015-06-26 2016-12-29 Abbvie Inc. Solid pharmaceutical compositions for treating hcv
CR20180088A (es) * 2015-07-17 2018-05-24 Abbvie Inc Composiciones farmacéuticas sólidas para el tratamiento del vhc
JP7179758B2 (ja) * 2017-04-25 2022-11-29 大塚製薬株式会社 摂取可能なイベントマーカを有するリシノプリル組成物
WO2020068510A1 (en) 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
ATE326240T2 (de) * 2000-04-10 2006-06-15 Nicholas John Wald Zusammensetzung zur prävention kardiovaskulärer erkrankungen
US6462174B1 (en) * 2001-06-25 2002-10-08 Astrazeneca Ab Amorphous compound
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
SG139601A1 (en) * 2002-02-05 2008-02-29 Ricoh Kk Ink-jet recording ink, ink-jet recording ink set, ink cartridge, ink-jet printer, and ink-jet printing method
CA2379887C (en) * 2002-04-09 2004-01-20 Bernard Charles Sherman Stable tablets comprising simvastatin
NZ544784A (en) * 2003-07-28 2009-11-27 Reddys Lab Inc Dr Treatment and prevention of cardiovascular events using a beta-adrenergic receptor antagonist, a diuretic, an inhibitor of HMG CoA reductase, an inhibitor of the rennin-angiotensin system and asprin; wherein acidic and basic components are separated.
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets

Also Published As

Publication number Publication date
ES2300188B1 (es) 2009-05-01
AU2007253580A1 (en) 2007-11-29
CA2652838A1 (en) 2007-11-29
US20090196922A1 (en) 2009-08-06
BRPI0712267A2 (pt) 2012-01-17
NO20084998L (no) 2009-02-23
CY1110097T1 (el) 2015-01-14
CN101453992A (zh) 2009-06-10
SI2026769T1 (sl) 2010-08-31
ES2300188A1 (es) 2008-06-01
AU2007253580B2 (en) 2012-03-22
RU2008151105A (ru) 2010-06-27
DE602007005372D1 (de) 2010-04-29
ES2342905T3 (es) 2010-07-16
AR061047A1 (es) 2008-07-30
PT2026769E (pt) 2010-06-11
HK1129577A1 (en) 2009-12-04
TW200812647A (en) 2008-03-16
MX2008014782A (es) 2008-11-28
WO2007134870A1 (en) 2007-11-29
JP2009537583A (ja) 2009-10-29
UY30365A1 (es) 2007-08-31
KR20090020577A (ko) 2009-02-26
EP2026769B1 (en) 2010-03-17
PL2026769T3 (pl) 2010-09-30
ATE460924T1 (de) 2010-04-15
EP2026769A1 (en) 2009-02-25
RU2445088C2 (ru) 2012-03-20

Similar Documents

Publication Publication Date Title
ATE460924T1 (de) Zweischichtige tablette zur verhinderung von kardiovaskulären ereignissen
DK2277509T3 (da) DPP IV inhibitorformuleringer
DK3178792T3 (da) Fremgangsmåde til aflejringshæmning
EP2111243A4 (en) CARDIOVASCULAR INTERVENTIONS
DK4218732T3 (da) Tabletter omfattende eltrombopag-olamin
IL198186A (en) Mphosph1 derived peptide vaccines
EP2025003A4 (en) STRUCTURES WITH SEVERAL COLUMNS
DE602007008788D1 (de) Bildschirmstandfuß
DK1948678T3 (da) Forbindelser til enzyminhibering
DK2069144T3 (da) Flerlagsfilm til solbeskyttelse
SE0600995L (nl) Detektorresponsmodellering
DK2408468T3 (da) Anvendelse af NKp46 til forebyggelse af type 1-diabetes
DK1942967T3 (da) Fremgangsmåde til dosering af medikamenter
DK2251019T3 (da) Middel til forebyggelse af alkoholhepatopati
DE502007005032D1 (de) Der Astromischer
EP1993006A4 (en) CHRONOGRAPH WATCH
EP2057985A4 (en) DRAGEE
DE112007002678A5 (de) Uhrengehäuse
NO20041408L (no) Beskyttelse av et pakningselement.
DK1856035T3 (da) Fremgangsmåde til fremstilling af beskyttelse amidiner
DE602006021746D1 (de) Asymmetrischer ringförmiger Detektor
DK1973410T3 (da) Fremgangsmåde til mængdedeling af dej
DE602006004698D1 (de) Plasma-Bildschirm
EP2043598A4 (en) PERFORATED TABLET WITH EXTENDED RELEASE
EP2050456A4 (en) COMPRESSED